Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 21.5% in the third quarter, HoldingsChannel reports. The firm owned 1,993 shares of the specialty pharmaceutical company’s stock after purchasing an additional 352 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Supernus Pharmaceuticals were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares during the period. Fidelis Capital Partners LLC acquired a new position in Supernus Pharmaceuticals during the 1st quarter worth $33,000. EntryPoint Capital LLC acquired a new position in Supernus Pharmaceuticals during the 1st quarter worth $43,000. Meeder Asset Management Inc. acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth $47,000. Finally, Innealta Capital LLC acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth $51,000.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 0.1 %

Shares of Supernus Pharmaceuticals stock opened at $34.74 on Wednesday. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 386.00 and a beta of 0.86. The business has a fifty day simple moving average of $33.02 and a 200-day simple moving average of $30.50. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $23.05 and a fifty-two week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company’s revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. Analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.